Researchers at University of Limerick have developed an exciting new
technology for the selection of better quality sperm for use in
assisted human reproduction.
With an estimated one in six couples experiencing infertility
problems, the microfluidics technology developed at UL could offer some
hope to those seeking to start a family.
neoMimix, a start-up from the University of Limerick, has been
announced as a winner of the EIT Health Headstart competition for 2020.
The prestigious competition supports the most innovative European
start-ups to accelerate their market launch through a €40,000 cash
prize.
Using funding secured from Enterprise Ireland’s Commercialisation
Fund, the UL researchers have developed an exciting new
microfluidics-based technology for the selection of better quality sperm
for use in assisted human reproduction.
“Infertility problems have been driven by increasing maternal age as
well as by the halving of sperm counts over the last 40 years,” said
Dr Sean Fair, Reproductive Biologist and project lead at UL.
“The most common fertility treatment couples undergo is
in vitro
fertilisation (IVF) and despite major advances in IVF over the last 40
years, two out of three cycles fail resulting in financial and emotional
pain for couples.
“While little can be done to improve the number or quality of women’s
eggs, men normally produce tens of millions of sperm yet only one is
required to fertilise an egg. Despite the large number of sperm produced
by men, very few are normal,” he explained.
The technology developed at UL uses microfluidics to mimic the
journey sperm would travel in the female reproductive tract, thereby
selecting the fittest and most functional sperm, which can then be used
in IVF to improve outcomes.
Working with fertility clinics, the team have demonstrated that the
selected sperm have significantly better DNA integrity than that
selected by currently used methods.
The solution provides the most natural, ex-vivo, biomimicry of the
female reproductive tract for sorting and selecting the highest grade,
lowest DNA fragmented sperm in a simple and fully traceable process.
“Women whose male partners have poor sperm DNA integrity are twice as
likely to have a miscarriage and therefore by selecting only sperm with
intact DNA the risk of miscarriage can be significantly reduced,” said
Dr Fair.
“Sperm naturally swim up the female reproductive tract on their way
to meet the egg in the fallopian tube and en route they must swim
against an outward flow of mucus that is secreted around the time of
ovulation. This means that only the fittest sperm reach the egg,” he
explained.
“The technology developed at UL replicates this journey on a
micro-device so that sperm swim against an active fluid flow within
micro-channels, mimicking what happens naturally. The fittest sperm are
then selected for use in fertility treatment.
“It is the result of over five years of painstaking work by the UL
team as they have optimised the architecture of the micro-device and
fluid flow profiles to ensure that only the best quality sperm are
selected. The team are now working on further clinical validation of the
technology after which regulatory approval will be sought,” he added.
The research is a multidisciplinary collaboration between Dr Fair, Ms
Karen Browne (Commercial Lead), Dr David Newport (Fluidics Engineer),
Professor Leonard O’Sullivan and Dr Eoin White (Product Design) as well
as with local fertility clinics.